Eternygen

About:

Eternygen focuses on research and development of innovative drugs using a network of renowned scientists & contract research organizations.

Website: http://www.eternygen.de

Top Investors: Evotec, Epidarex Capital, VC Fonds Technologie Berlin

Description:

Eternygen is a Berlin based start up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen’s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Eternygen’s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity. Company’s emphasis is the development of a safe and effective drug for treatment of these widespread diseases via targeted adjustment of underlying metabolic failure.

Total Funding Amount:

8M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Berlin, Berlin, Germany

Founded Date:

2012-06-01

Founders:

Andreas Birkenfeld, Jens Jordan, Marco Janezic

Number of Employees:

1-10

Last Funding Date:

2017-01-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai